Generated by AI
Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and providing novel therapies for hematologic disorders and cancer. The company’s current portfolio centers on commercial products and clinical-stage programs that address blood cancers and related immune-driven conditions, with an emphasis on targeted small-molecule medicines. Its marketed therapies support treatment in specialized physician markets, including hematology and oncology, while its research pipeline includes additional candidates designed to modulate key signaling pathways involved in disease progression. Rigel Pharmaceuticals also works through collaboration and licensing activities that support the development and commercialization of its products. Headquartered in South San Francisco, California, and founded in 1996, Rigel Pharmaceuticals plays a focused role in the biopharmaceutical market by supplying therapies for complex conditions with limited treatment options.
Website611 Gateway Boulevard
South San Francisco, CA, 94080
United States
Summary of Nov 10's posts. Generated by AI.
Summary of Aug 5's posts. Generated by AI.
Summary of Dec 2's posts. Generated by AI.
Summary of Mar 3's posts. Generated by AI.
Investors talking about RIGL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.